Bookmark and Share

BioActivity Data for Compound naloxonazine (CID 9576413)

BioActivity Outcomes:
Active(5)
 
 
Inactive(4)
 
 
Unspecified(130)
 
 
Top Targets:
7tm 4(30)
 
 
 
p450(8)
 
 
prostaglandin..(2)
 
 
Tryp SPc(2)
 
 
STKc ERK1 2 l..(2)
 
 
BioAssay Types:
Confirmatory(116)
 
 
 
Literature(3)
 
 
 
BioAssay Categories:
In vitro(132)
 
 
 
Biochemical(132)
 
 
 
Toxicity(1)
 
 
ADME(1)
 
 
Cell-based(84)
 
 
 
BioActivity Types:
IC50(116)
 
 
 
EC50(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 139    Data Row: 139   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID124960987]
IC50 0.0072DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625163, Type: confirmatory]Mu-type opioid receptor [gi:2851402]
View
2
[SID124960987]
IC50 0.085DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) [AID625162, Type: confirmatory]Kappa-type opioid receptor [gi:116242691]
View
3
[SID124960987]
IC50 0.136DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) [AID625161, Type: confirmatory]Delta-type opioid receptor [gi:311033488]
View
4
[SID124960987]
EC50 16Cytotoxicity against BESM cells after 88 hrs by HTS assay [AID547621, Type: Literature]
View
5
[SID124960987]
EC50 17Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay [AID547622, Type: Literature]
View
6
[SID124960987]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: confirmatory]
View
7
[SID124960987]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: confirmatory]
View
8
[SID124960987]
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
9
[SID124960987]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: confirmatory]
View
10
[SID124960987]
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
11
[SID124960987]
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
12
[SID124960987]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: confirmatory]
View
13
[SID124960987]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: confirmatory]
View
14
[SID124960987]
IC50 DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) [AID625244, Type: confirmatory]Prostaglandin G/H synthase 2 [gi:3915797]
View
15
[SID124960987]
IC50 DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) [AID625259, Type: confirmatory]Estrogen receptor beta [gi:6166154]
View
16
[SID124960987]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) [AID625220, Type: confirmatory]5-hydroxytryptamine receptor 4 [gi:6224984]
View
17
[SID124960987]
IC50 DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) [AID625248, Type: confirmatory]Cytochrome P450 2C9 [gi:6686268]
View
18
[SID124960987]
IC50 DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) [AID625171, Type: confirmatory]Potassium voltage-gated channel subfamily H member 2 [gi:7531135]
View
19
[SID124960987]
IC50 DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) [AID625182, Type: confirmatory]Mitogen-activated protein kinase 14 [gi:2499600]
View
20
[SID124960987]
IC50 DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) [AID625213, Type: confirmatory]B2 bradykinin receptor [gi:2506481]
View